RxDoctor Payments Data

Rajib Bhattacharya, MD

Endocrinology, Diabetes & Metabolism · Kansas City, MONPI 1477553204

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,817 of the $49,253 with a category attached, or 80.8%. 10 manufacturers reported payments, led by Radius Health, Inc. at 42.7% of the total. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,253in general payments, 2019–2025

Across 83 payments — averaging $593.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$21K
  • Ascendis Pharma Endocrinology Inc$15K
  • Antares Pharma, Inc.$11K
  • AstraZeneca$1K
  • Amgen$901
  • Pfizer$110
  • plus $185 from 4 others

What the payments were for

  • Consulting fees$4,5759%
  • Speaking & faculty fees$39,81781%
  • Travel & lodging$2,7576%
  • Food & beverage$2,0794%
  • Education$240%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,253 in reported general payments places this provider in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$13,352
Medicare patients
79
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$70,941
JardianceEmpagliflozin50$59,437
OzempicSemaglutide26$47,956
FarxigaDapagliflozin Propanediol51$37,528
Tresiba Flextouch U-100Insulin Degludec13$14,683
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,457
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,876
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$2,662
Ultra-Fine Short Pen NeedlePen Needle, Diabetic29$1,721
Hydrocortisone21$1,339
SynthroidLevothyroxine Sodium18$1,318
Levothyroxine Sodium164$1,029
Metformin Hcl70$707
Alendronate Sodium84$634
Testosterone Cypionate42$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,050$37,52851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →